That these treatments are helping people curb their eating should be no surprise: that is exactly what they are meant to do, by mimicking the satiety hormone GLP-1 (see “How they work”, below).

Spending growth for simple medications used to treat common health problems is outstripping spending growth for pricey medications used to treat complex and chronic conditions, according to a new ...

While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 (GLP-1) agonists in the medical world. Eli Lilly ( LLY -0.50%) has emerged ...

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and ...

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist ... to assess the efficacy and tolerability of different titration-free weekly doses of MET-097i.

In this article, we are going to take a look at where Global Partners LP (NYSE:GLP) stands against other best pipeline and MLP stocks to invest in according to analysts. The global pipeline market ...

Madison Burgess decided to get serious about weight loss when the scale hit 91 kilograms (200 pounds). She began taking Ozempic. The medication worked better than she ever thought possible: even ...

As Congress gears up to pass President Trump’s massive legislative package, one of the biggest fights is over the future of Medicaid. To make their targeted budget numbers, Republicans will ...

The issuer is solely responsible for the content of this announcement.

The FDA removed Lilly’s GLP-1 medications, Mounjaro and Zepbound, from its shortage list in December 2024, followed by Novo Nordisk’s Ozempic and Wegovy in February 2025. This decision was ...

The addition of a candidate targeting glucagon, as well as GLP-1 and GIP ... Each group adopted a dose titration method, with subcutaneous injection once a week for 12 consecutive weeks.